{"protocolSection": {"identificationModule": {"nctId": "NCT05552976", "orgStudyIdInfo": {"id": "CA057-008"}, "organization": {"fullName": "Bristol-Myers Squibb", "class": "INDUSTRY"}, "briefTitle": "A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)", "officialTitle": "A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2", "acronym": "SUCCESSOR-2"}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Bristol-Myers Squibb", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2."}, "conditionsModule": {"conditions": ["Relapsed or Refractory Multiple Myeloma"], "keywords": ["BMS-986348", "CC-92480", "Carfilzomib", "Dexamethasone", "Multiple Myeloma", "Mezigdomide"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "This is a two-stage inferentially seamless design.", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE", "maskingDescription": "This is an open-label study; however, any review of aggregate study data by the Sponsor will be performed in a blinded manner."}}, "enrollmentInfo": {"count": 525, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "MeziKd (Mezigdomide + Carfilzomib + Dexamethasone)", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Mezigdomide", "Drug: Carfilzomib", "Drug: Dexamethasone"]}, {"label": "Kd (Carfilzomib + Dexamethasone)", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Carfilzomib", "Drug: Dexamethasone"]}], "interventions": [{"type": "DRUG", "name": "Mezigdomide", "description": "Specified dose on specified days", "armGroupLabels": ["MeziKd (Mezigdomide + Carfilzomib + Dexamethasone)"], "otherNames": ["BMS-986348", "CC-92480"]}, {"type": "DRUG", "name": "Carfilzomib", "description": "Specified dose on specified days", "armGroupLabels": ["Kd (Carfilzomib + Dexamethasone)", "MeziKd (Mezigdomide + Carfilzomib + Dexamethasone)"], "otherNames": ["Kyprolis"]}, {"type": "DRUG", "name": "Dexamethasone", "description": "Specified dose on specified days", "armGroupLabels": ["Kd (Carfilzomib + Dexamethasone)", "MeziKd (Mezigdomide + Carfilzomib + Dexamethasone)"], "otherNames": ["Decadron", "Dex"]}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria\n\n- Participant has documented diagnosis of multiple myeloma and measurable disease, defined as any of the following:.\n\ni) Myeloma-protein (M-protein) \u2265 0.5 grams/deciliter (g/dL) by serum protein electrophoresis (sPEP), or.\n\nii) M-protein \u2265 200 milligrams (mg)/24-hour urine collection by urine protein electrophoresis (uPEP) or,.\n\niii) For participants without measurable disease in sPEP or uPEP: serum free light chain levels \\> 100 mg/liter (L) (10 mg/dL) involved light chain and an abnormal \u03ba/\u03bb free light chain ratio.\n\n* Participant has received at least one prior line of anti-myeloma therapy. Note: One line can contain several phases (e.g., induction, \\[with or without\\] hematopoietic stem cell transplant, (with or without) consolidation, and/or \\[with or without\\] maintenance therapy).\n* Participant must have received prior treatment with lenalidomide and at least 2 cycles of an anti-CD38 monoclonal antibody (mAb) (participants who were intolerant of an anti-CD38 mAb and received \\< 2 cycles are still eligible).\n* Participant achieved minimal response or better to at least 1 prior anti-myeloma therapy.\n* Participant must have documented disease progression during or after their last antimyeloma regimen.\n\nExclusion Criteria\n\n* Participant who has had prior treatment with mezigdomide or carfilzomib.\n* Participant has previously received allogeneic stem cell transplant at any time or received autologous stem cell transplant within 12 weeks of initiating study treatment.\n* Other protocol-defined Inclusion/Exclusion criteria apply.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "BMS Clinical Trials Contact Center www.BMSClinicalTrials.com", "role": "CONTACT", "phone": "855-907-3286", "email": "Clinical.Trials@bms.com"}, {"name": "First line of the email MUST contain the NCT# and Site #.", "role": "CONTACT"}], "overallOfficials": [{"name": "Bristol-Myers Squibb", "affiliation": "Bristol-Myers Squibb", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"seeAlsoLinks": [{"label": "BMS Clinical Trial Information", "url": "https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"}, {"label": "BMS Clinical Trial Patient Recruiting", "url": "https://www.BMSClinicalTrials.com"}]}}, "hasResults": false}